ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

First Store-Brand Version of Nexium 24HR Arrives


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

man reading a pill bottle in a pharmacy

A cheaper, store-brand version of popular over-the-counter (OTC) heartburn medicine Nexium 24HR has arrived on store shelves across the U.S.

Michigan-based drug-maker Perrigo Company PLC announced it began delivering the first store-band FDA approved equivalents of esomeprazole magnesium on September 27. The Perrigo products are boxed as retailers’ own label and sold as a lower-priced alternative to the name brand.

Nexium 24HR is one of the biggest-selling over-the-counter treatments for frequent heartburn, with annual sales estimated at more than $300 million. Competition from a less expensive version could eat into profits for pharmaceutical company Pfizer, which has had exclusive rights to the OTC version of Nexium since 2014.

Are you suffering from complications after taking a PPI? Get a Free Case Review

Both Nexium 24HR and the new store-brand equivalent are part of a class of drugs called proton pump inhibitors (PPIs), which also includes Prilosec and Prevacid. PPIs have been manufactured in prescription and over-the-counter versions for years. The U.S. Food and Drug Administration approved the first generic version of prescription Nexium in 2015, and Perrigo’s OTC store brand version in August.

PPIs: Risks from Being Over-Prescribed and Over-Used

PPIs have been criticized as one of the most over-prescribed and over-used drugs in the U.S. Some research has found that anywhere from 20 to 70 percent of people taking them had a form of heartburn the drugs aren’t meant to treat.

The Perrigo store-brand drugs are intended to treat frequent heartburn – heartburn that occurs two or more days a week. But it and other PPIs do not provide immediate relief from heartburn. The Perrigo label says it is “not intended for immediate relief of heartburn.” It may take anywhere from 1 to 4 days to take effect.

Studies have associated PPIs with serious complications including as much as a 20 to 50 percent increased risk of chronic kidney disease compared to people who don’t take PPIs.

The FDA has issued multiple warnings about other health risks of PPIs, including:

  • Risk of acute interstitial nephritis (AIN) – a condition that can lead to kidney failure
  • Increased risk of bone fractures in the spine, hip and wrist
  • Diarrhea associated with a difficult to treat bacterial infection called C. diff.

To reduce risks, the U.S. Food and Drug Administration says PPIs should not be taken for more than 14 days in a row unless under a doctor’s supervision. Label information for the new Perrigo store-brand shows each package contains a single, 14-day course of the drug. The Perrigo labels also list the FDA guidelines warning people should to wait at least four months before taking the next 14-day course.

Perrigo: A Multi-Billion Dollar Drug Company You may have Never Heard Of

Perrigo Company PLC originated in 1887 as a manufacturer of patent medicines in Allegan, Michigan. It was an early player in manufacturing store-branded products.

People who have never heard of the company may have purchased its products in the past. Perrigo’s website says the company is the “world’s largest manufacturer of OTC healthcare products…for the store brand market.”

Those products include cold and allergy medications, pain relievers and fever reducers, heartburn medications and smoking cessation products. The company also manufactures or markets generic prescription drugs in the U.S.

Perrigo’s U.S. executive offices are still based in Michigan, but it is incorporated in the Republic of Ireland and operates more than 100 facilities around the world. According to its annual report, Perrigo’s net sales more than doubled to nearly $5.3 billion from 2015 to 2016 following a series of acquisitions of other companies.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By

12 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. FDA. (2014, December). Nexium Label. Retrieved from:
  2. Antoniou, T., et al. (2015, April 16). Proton Pump Inhibitors and the Risk of Acute Kidney Injury in Older Patients: A Population-Based Cohort Study. Retrieved from:
  3. Forgacs, I. and Loganayagam, A. (2008, January 5). Overprescribing Proton Pump Inhibitors. Retrieved from:
  4. FDA. (2015, January 26). FDA Approves First Generic Esomeprazole. Retrieved from:
  5. FDA. (2017, August 18). FDA Approval Letter. Retrieved from:
  6. Drug Store News. (2017, August 21). Perrigo Prepping Launch of Nexium 24HR Equivalent Following FDA OK. Retrieved from:
  7. Salazar, D. (2017, September 27). Perrigo Ships First-to-Market Store-Brand Nexium 24HR. Retrieved from:
  8. FDA. (2017, August 18). Perrigo Esomeprazole Magnesium Label. Retrieved from:
  9. FDA. (2011, March 23). FDA Drug Safety Communication: Possible Increased Risk of Fractures of the Hip, Wrist, and Spine with the Use of Proton Pump Inhibitors. Retrieved from:
  10. FDA. (2012, February 8). FDA Drug Safety Communication: Clostridium Difficile Associated Diarrhea can be Associated with Stomach Acid Drugs Known as Proton Pump Inhibitors (PPIs). Retrieved from:
  11. Perrigo Company PLC. (n.d.). Our History. Retrieved from:
  12. Perrigo Company PLC. (2017, May 22) Perrigo 2016 Annual Report. Retrieved from:
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(866) 587-0279